Literature DB >> 14534894

Reirradiation and hyperthermia in rectal carcinoma: a retrospective study on palliative effect.

Jorine H M Juffermans1, Patrick E J Hanssens, Wim L J van Putten, Gerard C van Rhoon, Jacoba van Der Zee.   

Abstract

BACKGROUND: The objective of this study was to evaluate the palliative effect of reirradiation and hyperthermia in patients with unresectable, recurrent colorectal carcinoma.
METHODS: The medical records of 54 patients with unresectable, recurrent colorectal carcinoma that caused pain and who were treated with reirradiation and hyperthermia, were evaluated retrospectively. Previous radiotherapy was given up to a total dose ranging from 25-70 grays (Gy). The median interval between prior radiotherapy and reirradiation was 22 months (range, 4-97 months). The total reirradiation dose varied from 24 Gy to 32 Gy given in fractions of 4 Gy twice weekly. Three or four hyperthermia treatments were given once weekly. Toxicity was registered. The influence of World Health Organization (WHO) performance status, maximum tumor dimension, and time between first radiotherapy and reirradiation on therapeutic outcome was evaluated. The results of this study were compared with published results on patients who received radiotherapy with or without hyperthermia.
RESULTS: Forty-seven patients (87%) completed the planned treatment schedule. The maximum toxicity was Grade 2. All patients were evaluated for palliative effect. The median follow-up was 10 months. A good or complete palliative effect was achieved in 72% of patients for a median duration of 6 months. Patients who had a better WHO performance status, smaller tumors, and a longer interval between first radiotherapy and reirradiation had slightly better outcomes, although none of those parameters reached statistical significance.
CONCLUSIONS: The described combined treatment was feasible and well tolerated. Comparison of results from radiotherapy plus hyperthermia with results after radiotherapy alone suggested that additional hyperthermia prolonged the duration of palliation. Firm proof of the contribution of hyperthermia will require performing a Phase III study. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Year:  2003        PMID: 14534894     DOI: 10.1002/cncr.11719

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Neoadjuvant Treatment Strategies: Advanced Radiation Alternatives.

Authors:  Bruce D Minsky
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

Review 2.  [Therapy of locally recurrent rectal carcinoma].

Authors:  H G Hempen; H R Raab
Journal:  Chirurg       Date:  2009-04       Impact factor: 0.955

Review 3.  Radiotherapy in conjunction with superficial and intracavitary hyperthermia for the treatment of solid tumors: survival and thermal parameters.

Authors:  S Triantopoulou; E Efstathopoulos; K Platoni; N Uzunoglou; N Kelekis; V Kouloulias
Journal:  Clin Transl Oncol       Date:  2012-11-21       Impact factor: 3.405

4.  ACR Appropriateness Criteria®-Recurrent Rectal Cancer.

Authors:  Andre A Konski; W Warren Suh; Joseph M Herman; A William Blackstock; Theodore S Hong; Matthew M Poggi; Miguel Rodriguez-Bigas; William Small; Charles R Thomas; Jennifer Zook
Journal:  Gastrointest Cancer Res       Date:  2012-01

5.  Robotic image-guided reirradiation of lateral pelvic recurrences: preliminary results.

Authors:  Sylvain Dewas; Jean Emmanuel Bibault; Xavier Mirabel; Philippe Nickers; Bernard Castelain; Thomas Lacornerie; Hajer Jarraya; Eric Lartigau
Journal:  Radiat Oncol       Date:  2011-06-23       Impact factor: 3.481

6.  Response to chemotherapy in patients with recurrent rectal cancer in previously irradiated area.

Authors:  W J Alberda; B C Haberkorn; W G Morshuis; J F Oudendijk; J J Nuyttens; J W A Burger; C Verhoef; E van Meerten
Journal:  Int J Colorectal Dis       Date:  2015-06-17       Impact factor: 2.571

Review 7.  Integrating Hyperthermia into Modern Radiation Oncology: What Evidence Is Necessary?

Authors:  Jan C Peeken; Peter Vaupel; Stephanie E Combs
Journal:  Front Oncol       Date:  2017-06-30       Impact factor: 6.244

8.  Re-irradiation: outcome, cumulative dose and toxicity in patients retreated with stereotactic radiotherapy in the abdominal or pelvic region.

Authors:  Huda Abusaris; M Hoogeman; Joost J Nuyttens
Journal:  Technol Cancer Res Treat       Date:  2012-05-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.